Crystalline forms of a pharmaceutical compound
AssigneeCephalon, Inc.
InventorsMichael Harold Rock, Heidi Lopez De Diego, Kim Lasse Christensen, Ole Nielsen, Anders Buur, Mark Howells
Life of this patent
Estimating the term…
Abstract
Described are crystalline forms of the pharmaceutical compound “[9S-(9α,10β,12α)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9, 12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester”, as well as methods for their use and preparation.
Claims14
A crystalline form of Compound I, which compound has the formula
- wherein the crystalline form of Compound I exhibits one or more of:
- (i) the X-Ray powder diffractogram shown in FIG. 1 as measured using CuKα radiation;
- (ii) reflections in the X-Ray powder diffractogram as measured using CuKα radiation at 2-theta angles:
- 5.2, 10.1, 10.4, 13.2, 15.1, and 25.1;
- (iii) the solid state Carbon-13 NMR spectrum shown in FIG. 7;
- or (iv) the NIR reflectance spectrum shown in FIG. 10.
A crystalline form of compound I, which compound has the formula
- wherein the crystalline form of Compound I exhibits one or more of:
- (i) the X-Ray powder diffractogram shown in FIG. 3 as measured using CuKα radiation;
- (ii) reflections in the X-Ray powder diffractogram as measured using CuKα radiation at 2-theta angles:
- 9.6, 11.5, 12.5, 16.7, 19.3, and 28.1;
- (iii) the solid state Carbon-13 NMR spectrum shown in FIG. 9;
- or (iv) the NIR reflectance spectrum shown in FIG. 12.
A crystalline form of Compound I, which compound has the formula
- wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuKα radiation at 2-theta angles:
- 9.7, 12.1, 16.1, 18.3, 22.1, 22.2, 25.7, and 25.8.
A method for preparing crystalline Compound I, comprising forming crystalline Compound I in a solvent of methanol with 0% to about 8% water, wherein Compound I has the formula
Dependencies are inferred from the claim text.